HEALTHSTORY 1130· JUNE 24, 2026

WHO-Backed Clinical Trial to Test Remdesivir and MBP-134 Against Bundibugyo Ebolavirus in DRC

A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 1129Asia Technology Stocks Mostly Rebound After Global Rout; Samsung Gains 9%NEXT STORY 1131 →Federal Judge Blocks Texas Prosecutors From Subpoenaing Transgender Patient Records at New York Hospitals

Keep reading

More from the desk.

02HEALTH

Novartis shares drop 11% on drug failure as biosimilar gap threatens $200 billion in savings

A failed clinical trial wiped nearly $30 billion from Novartis's market value this week after shares fell 11% in a single session, erasing all the gains the stock had made since the start of the year. The drug that failed, del-desiran, was…

health2 MIN

10HEALTH

EU legal adviser hands pharma a win on wastewater costs

Pharmaceutical and cosmetics companies across Europe may be off the hook for the largest share of a continent-wide water cleanup effort, after a legal adviser to the EU's top court recommended striki

health2 MIN

11HEALTH

FDA clears first drug to target muscle loss in spinal muscular atrophy

Federal regulators approved a drug on Friday for spinal muscular atrophy, a rare neurological condition where the nerve cells that signal muscles to move gradually deteriorate. The drug, Isembyld, is the first approved therapy to directly…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk